Related Experiment Video

Updated: Aug 23, 2025

Author Spotlight: Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus
06:45

Author Spotlight: Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus

Published on: June 2, 2023

2.3K

Serratiopeptidase: An integrated View of Multifaceted Therapeutic Enzyme

Sreelakshmi R Nair1, Subathra Devi C1

  • 1Department of Biotechnology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore 632014, India.

Biomolecules
|October 27, 2022
PubMed

Insights

Serratiopeptidase, a microbial enzyme, offers a safe and cost-effective anti-inflammatory alternative to NSAIDs. Its potential applications extend to treating arthritis, cancer, and COVID-19 complications.

Area of Science:

  • Microbiology
  • Enzymology
  • Pharmacology

Background:

  • Microbial products have a long history in disease treatment.
  • Serratiopeptidase, an enzyme from *Serratia* sp., is a well-established anti-inflammatory agent.
  • There is a continuous need for novel microbial strains for enhanced enzyme production.

Purpose of the Study:

  • To review the properties and therapeutic potential of serratiopeptidase.
  • To explore industrial production and analytical techniques for serratiopeptidase.
  • To highlight serratiopeptidase's role in managing COVID-19.

Main Methods:

  • Literature review of scientific databases.
  • Analysis of existing studies on serratiopeptidase production and application.
  • Exploration of recombinant strain development for enzyme enhancement.

Main Results:

  • Serratiopeptidase is a cheaper and safer alternative to NSAIDs.
  • The enzyme shows promise for treating arthritis, diabetes, cancer, and thrombolytic conditions.
  • Combination therapy with antibiotics is effective for postoperative swelling.

Conclusions:

  • Serratiopeptidase possesses multifaceted therapeutic properties.
  • Further research into recombinant strains is needed to optimize enzyme production.
  • Serratiopeptidase shows potential in addressing COVID-19 related respiratory issues.
Keywords:
COVID-19Serratia sp.anti-biofilmanti-inflammatoryfibrinolyticmucolyticserratiopeptidase

More Related Videos

Use of Recombinant Fusion Proteins in a Fluorescent Protease Assay Platform and Their In-gel Renaturation19:23

Use of Recombinant Fusion Proteins in a Fluorescent Protease Assay Platform and Their In-gel Renaturation

Published on: January 16, 2019

9.3K
Nanosensors to Detect Protease Activity In Vivo for Noninvasive Diagnostics10:50

Nanosensors to Detect Protease Activity In Vivo for Noninvasive Diagnostics

Published on: July 16, 2018

16.4K

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
637
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
79.0K
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
508
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
128
Protein Digestion01:02

Protein Digestion

Protein digestion begins in the stomach, where the highly acidic environment can easily disrupt protein structure by exposing the peptide bonds of polypeptide chains. After polypeptide chains are broken into individual amino acids by a series of digestive enzymes, the amino acids are transported to the liver via the bloodstream to produce energy.
104.6K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
233